Program
EDI-048
In Novartis's pipeline, CpPI(4)K inhibitor
. Its studies are mostly in Cryptosporidiosis, led by Novartis.
Furthest: phase 2, since Nov 18, 20252 company-led studies, 1 open or runningNext primary completion: Mar 23, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 21 open or running | phase 2since Nov 18, 2025 | Mar 2, 2022 | Mar 23, 2027phase 2 · NCT07249463 |
- Named in Novartis’s own pipeline as
EDI048
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05275855 · 110 enrolled · United Kingdom
- Nov 18, 2025Phase 2 study in CryptosporidiosisPhase 2 reachedNCT07249463 · 80 planned · United States
Ahead
- Mar 23, 2027Primary completion: phase 2 study in CryptosporidiosisNCT07249463
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“CpPI(4)K inhibitor”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07249463Cryptosporidiosis · United States | 2 | Recruiting | Mar 23, 2027 | 80 |
| NCT05275855Healthy Volunteers · United Kingdom | 1 | Completed | Dec 18, 2024 | 110 |
How it is read
Names in the registry
- “EDI048”, 2 entries
Conditions, from the studies’ own filings
- Cryptosporidiosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.